Kim, Chul Hee Choi, Yoon Seok Moon, Ji Young Kim, Duck Yong Lee, So Yeon Lee, Hyo Jin Yun, Hwan Jung Kim, Samyong Jo, Deog Yeon Song, Ik Chan
...
Published in
The Korean journal of internal medicine
Few studies have addressed whether there are differences in clinical efficacy between intravenous methylprednisolone (methyl-Pd) and intravenous immunoglobulin (IVIg) use. We retrospectively compared platelet responses and toxicities associated with these two treatments in adult patients with immune thrombocytopenia. Patients received intravenous m...
Rama Krishna, Malla Gottam, Uma Sri Mahendra, Nagendra
Published in
Respiratory Medicine Case Reports
Immune thrombocytopenia is an autoimmune condition with increased platelet destruction. Immune thrombocytopenic purpura is an uncommon and rare manifestation of tuberculosis. A search of the literature available on TB-associated ITP identified only around 50 cases published between 1964 and 2016. We present an uncommon and interesting case of sever...
Friedman, Jeremy N Beck, Carolyn E
Published in
Paediatrics & child health
This practice point applies to children aged 90 days through 17 years who have typical, newly diagnosed primary immune thrombocytopenia (ITP). Current recommendations on management and information from recent studies are summarized with the goal of decreasing variable practice among providers and improving patient-centred care. Options for initiall...
Friedman, Jeremy N Beck, Carolyn E
Published in
Paediatrics & Child Health
Le présent point de pratique porte sur les enfants âgés de 90 jours à 17 ans qui viennent de recevoir un diagnostic de thrombopénie immune (TPI) primaire classique. Les recommandations à jour sur la prise en charge et l’information tirée d’études récentes sont résumées afin de limiter la variabilité des pratiques chez les dispensateurs de soins et ...
Tastaldi, Luciano Krpata, David M. Prabhu, Ajita S. Petro, Clayton C. Haskins, Ivy N. Perez, Arielle J. Alkhatib, Hemasat Colturato, Iago Tu, Chao Lichtin, Alan
...
Published in
Surgical Endoscopy
BackgroundThe advent of newer second-line medical therapies (SLMT) for immune thrombocytopenia (ITP) has contributed to decreased rates of splenectomy, following a trend to avoid or delay surgery. We aimed to characterize the long-term outcomes of laparoscopic splenectomy (LS) for ITP at our institution, examining differences in LS efficiency when ...
Rungjirajittranon, Tarinee Owattanapanich, Weerapat
Published in
Journal of Medical Case Reports
BackgroundImmune thrombocytopenia is an acquired autoimmune disease. Recently, there has been evidence of thrombotic risk in patients with immune thrombocytopenia, but the mechanism is still inconclusive. Intravenous immunoglobulin infusion therapy is considered an efficient treatment; however, it still is associated with adverse events of fever, c...
Al-Samkari, Hanny Van Cott, Elizabeth M. Kuter, David J.
Published in
Annals of Hematology
The thrombopoietin receptor agonist romiplostim is used for the long-term treatment of chronic immune thrombocytopenia (ITP). ITP patients have an increased thrombotic risk, which could be exacerbated if romiplostim increased platelet hyperreactivity or caused spontaneous platelet aggregation. To investigate this possibility, this study examined pl...
Patient, Matthieu
Introduction : le purpura thrombopénique immunologique (PTI) est la plus fréquente des cytopénies auto-immunes. Le rituximab (RTX, anticorps monoclonal anti-CD20) représente actuellement une des options thérapeutiques de deuxième ligne, avec un taux de réponse globale initiale d’environ 60%. Cependant, la majorité des patients rechute. Dans ce cont...
Berrueco, Rubén Dapena, José Luis Sebastián, Elena Sastre, Ana
Published in
Anales de pediatria (Barcelona, Spain : 2003)
Immune thrombocytopenia (ITP) is a relatively common disorder in childhood. Although it usually achieves spontaneous remission at this age, the management of persistent or chronic ITP in children is still controversial. The aim of this article is to address current controversies related to the treatment of persistent, chronic, and refractory ITP in...
Audia, Sylvain Moulinet, Thomas Ciudad-Bonté, Marion Samson, Maxime Facy, Olivier Ortega-Deballon, Pablo Saas, Philippe Bonnotte, Bernard
Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We too...
